85
Participants
Start Date
January 27, 2022
Primary Completion Date
May 24, 2023
Study Completion Date
May 24, 2023
Cenegermin
Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
Vehicle
Vehicle was instilled with the same scheme of the test product
OCLI (Ophthalmic Consultants of Long Island), Garden City
Scheie Eye Institute, Philadelphia
Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica, Milan
The Johns Hopkins University, Baltimore
Toyos Clinic - Nashville, Nashville
Houston Eye Associates HEA - Gramercy Location, Houston
Lugene Eye Institute - Glendale Office, Glendale
AOU Gaspare Rodolico - Ospedale San Marco, Catania
Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center, Boston
AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica, Roma
Dompé Farmaceutici S.p.A
INDUSTRY